Loading...
Market
Story
BridgeBio Receives FDA Approval for Heart Disease Drug Attruby™ (acoramidis)
Nov 23, 2024, 12:12 AM
BridgeBio Pharma Inc. (BBIO) has received FDA approval for its drug Attruby™ (acoramidis), a near-complete TTR stabilizer (≥90%), to reduce cardiovascular death and hospitalization in patients with transthyretin amyloid cardiomyopathy (ATTR-CM). The approval will trigger a $500 million payment to BridgeBio under its royalty funding agreement. BridgeBio will provide further details on the Attruby label and access programs in a management call on November 22, 2024, at 8:00 pm ET. The approval is seen as a significant milestone for the company, and the share price is expected to react positively.
View original story
Similar markets
Less than 10 • 25%
10 to 20 • 25%
21 to 30 • 25%
More than 30 • 25%
None • 25%
One new state • 25%
Two new states • 25%
Three or more new states • 25%
India only • 25%
India and 1 other country • 25%
India and 2 other countries • 25%
India and 3 or more other countries • 25%
No expansion • 25%
1 additional country • 25%
2 additional countries • 25%
3 or more additional countries • 25%
